AMBRoSIA (A Multicentre Biomarker Resource Strategy In ALS) is an ambitious collaboration involving three leading research centres. It could help us understand motor neurone disease better than ever before. It could help develop a faster process for diagnosing the disease and may lead to better targeted treatments.

This is your chance to be a part of this exciting initiative – 100% of your donation will help to fund Project AMBRoSIA.

What does the project aim to do?

The research teams based in Oxford, London and Sheffield will collect and analyse thousands of samples taken from participants. They will look at how motor neurone disease progresses in different people. This will help us better understand the various types of motor neurone disease and how each type affects those living with the disease.

AMBRoSIA could eventually lead us to:

  • A faster process for diagnosing MND.
  • Earlier access to treatment, improving the prognosis for many patients.
  • Better understanding of the various types of MND and their speed of progression, meaning we can help patients according to their individual needs.
  • New drug testing based on different causes of MND, leading to bespoke approaches to treatment.
  • Ultimately, advances made from AMBRoSIA may even let us begin working towards developing preventative treatments for MND.

What are biomarkers?

Biomarkers are the ‘fingerprints’ of MND, chemical signals unique to the disease. This collaboration involves the collection of thousands of blood, cerebrospinal fluid and skin samples from each of our participants, combined with detailed monitoring of their disease every 3-6 months.

Finding the biomarkers unique to MND will help make the testing the effect of drugs and treatments much more accurate. In the future, these biomarkers may be critical in our search for a cure.

I’m absolutely motivated to see that we finally develop better treatments, if not a complete reversal of this disease. This project is unprecedented in how large it is, and it will involve over 1000 volunteers including 900 patients living with MND.  

 

Professor Martin Turner
University of Oxford
 

What does the project aim to do?

Our research teams will analyse thousands of samples taken from participants. They will look at how motor neurone disease progresses in different people. This will help us better understand the various types of MND and how each type affects those living with the disease.

AMBRoSIA could eventually lead us to:

  • A faster process for diagnosing MND.
  • Earlier access to treatment, improving the prognosis for many patients.
  • Better understanding of the various types of MND and their speed of progression, meaning we can help patients according to their individual needs.
  • New drugs testing according to different causes of MND, leading to bespoke approaches to treatment.
  • Ultimately, advances made from AMBRoSIA may even let us begin working towards developing preventative treatments for MND.

What are biomarkers?

Biomarkers are the ‘fingerprints’ of MND, chemical signals unique to the disease. We will analyse thousands of blood, cerebrospinal fluid and skin samples from each of our participants and monitor the progress of their disease every three months.

Finding the biomarkers unique to MND will make testing the effect of drugs and treatments much more accurate. In the future, these biomarkers may be critical in our search for a cure.

I’m absolutely motivated to see that we finally develop better treatments, if not a complete reversal of this disease. This project is unprecedented in how large it is, and it will involve over 1000 volunteers including 900 patients living with MND.  

 

Professor Martin Turner